Armistice Capital LLC Acquires Shares of 7,917,653 Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)

Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing.

Separately, Kingswood Wealth Advisors LLC acquired a new stake in Brainstorm Cell Therapeutics in the 1st quarter worth about $46,000. 14.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Thursday, July 11th. StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research note on Monday. They issued a “hold” rating for the company.

Brainstorm Cell Therapeutics Trading Up 4.3 %

NASDAQ:BCLI opened at $0.25 on Friday. The company has a market cap of $17.84 million, a P/E ratio of -0.80 and a beta of 0.35. Brainstorm Cell Therapeutics Inc. has a twelve month low of $0.13 and a twelve month high of $0.79. The company’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.41.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). During the same quarter in the previous year, the business earned ($0.27) earnings per share. On average, analysts expect that Brainstorm Cell Therapeutics Inc. will post -0.19 earnings per share for the current year.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.